|Day's Range||700.00 - 700.00|
|52 Week Range||700.00 - 701.00|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Kite stock jumped for the third straight day Thursday after rival Novartis presented data on a cancer drug that would have to be 20% better to hurt Kite.
NVS's Alcon reported 1% operational growth in revenues to ~$1.4 billion in 1Q17.